Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

18.77
-0.6500-3.35%
Post-market: 19.100.3306+1.76%19:40 EDT
Volume:2.76M
Turnover:52.08M
Market Cap:4.11B
PE:-11.99
High:19.30
Open:19.15
Low:18.63
Close:19.42
52wk High:21.27
52wk Low:3.52
Shares:219.14M
Float Shares:142.00M
Volume Ratio:1.01
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.62
PE(LYR):-11.65

Loading ...

Relay Therapeutics Q2 Net Income USD -83.707 Million Vs. IBES Estimate USD -74.2 Million

Reuters
·
Aug 07

Relay Therapeutics Q2 Operating Expenses USD 91.174 Million

THOMSON REUTERS
·
Aug 07

Relay Therapeutics Q2 EPS USD -0.41

THOMSON REUTERS
·
Aug 07

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

GlobeNewswire
·
Aug 07

Is Relay Therapeutics (RLAY) Turning Zovegalisib Updates Into a Credibility Test for Its Pipeline Strategy?

Simply Wall St.
·
Jul 31

Relay Therapeutics to Report Q2 Results After Markets Close

Reuters
·
Jul 31

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

GlobeNewswire
·
Jul 31

Relay Therapeutics is Maintained at Buy by Goldman Sachs

Dow Jones
·
Jul 21

Relay Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $29

THOMSON REUTERS
·
Jul 16

Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target

MT Newswires Live
·
Jul 16

Relay Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 16

Relay Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Jul 16

Relay Therapeutics CFO Thomas Catinazzo Sells 17,717 Common Shares Worth $331,104.73

Reuters
·
Jul 09

Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next

Simply Wall St.
·
Jul 08

Relay Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jul 08

U.S. Research Roundup- Alliant Energy, Prog Holdings, Travelers

Reuters
·
Jul 08

Relay Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $28

THOMSON REUTERS
·
Jul 08

Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 50,000 Shares for $954,500

Reuters
·
Jul 03

Relay Therapeutics Targets NRAS Cancers With New First-in-Human Trial

TIPRANKS
·
Jul 03

Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced?

Simply Wall St.
·
Jul 01